The global ligases enzyme market will generate a revenue of $631.7 million in 2030, and the market size will advance at a CAGR of 6.2% between 2021 and 2030. This is ascribed to the increasing prevalence of cancer and genetic disorders and the surging need for ligases in disease treatment.
Moreover, ligase is the most widely used enzyme in molecular biology since DNA repair and replication are required for every DNA experiment, which may also result in a wide spectrum of genetic abnormalities. These genetic abnormalities eventually result in neuro-generative/developmental problems as well as malignant growth-related illnesses.
Based on product, the T4 DNA ligase category is expected to witness the fastest growth, advancing at a CAGR of 6.8%, from 2021 to 2030, in the market. This can be because T4 DNA ligase is a highly efficient, precise, and fast enzyme intended to ligate cohesive and blunt-ended DNA inserts into plasmid vectors in 5–15 minutes. It is based on the use of T4 DNA ligase in conjunction with a premium 5x ligation buffer. Using traditional transformation protocols, the ligation reaction mixture is employed immediately for bacterial transformation. It allows for sticky or blunt end DNA ligation in five minutes at room temperature.
The research laboratories and institutions category lead the ligases enzyme market, accounting for $135.5 million revenue in 2021, and it is expected to continue its dominance during the forecast period as well. Research laboratories are at the forefront because they are major innovators of genetic testing. Also, these laboratories are essential facilities for both businesses and independent academic research institutions.
Moreover, in the market, research laboratories and institutions are the only ones working on developing new technologies to enable the discovery of chemical or biological modulators of approved ligases enzyme targets, as well as demonstrating modulation of the targets with high specificity through the use of chemical or biological modulators, resulting in beneficial effects for disease progression in clinically relevant models.
Key players in the market have been involved in various strategic developments, such as product launches and partnerships, to remain competitive and improve their position. For instance:
In June 2020, Codexis Inc. partnered with Molecular Assemblies Inc., to engineer enzymes and offer cost-effective and differentiated solutions for the enzymatic synthesis of DNA.
In January 2022, ArcticZymes Technologies introduced new products like ArcticZymes R2DTM Ligase, M-SAN HQ ELISA Kit, IsoPol BST+ High Concentration Glycerol FREE, and M-SAN HQ enzyme.
Major players operating in the ligases enzyme market include Agilent Technologies Inc., ArcticZymes Technologies ASA, Bio-Rad Laboratories Inc., Codexis Inc., F. Hoffmann-La Roche Ltd., Inspiralis Limited Inc., Merck KGaA, New England Biolabs (UK) Ltd., Promega Corporation, QIAGEN N.V., and BLIRT S.A.